About this visual
The design and clinical question behind a lower-dose oral semaglutide trial.
Sources & further reading
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

Originally posted Aug 2026 · By Joe Zucchi, PA-C, MPAS
1280 × 1599 px · PDF includes the original image and a link to this page.
The design and clinical question behind a lower-dose oral semaglutide trial.
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

A November 2026 overview of 12 investigational obesity therapies, spanning amylin-based treatments, GLP-1/GIP pathways, glucagon-containing combinations, and GLP-1 receptor agonists.

A six-slide overview of VK2735, covering injectable and oral Phase 2 results, exploratory maintenance dosing, dose-specific tolerability and Phase 3 programs.

A visual summary of sponsor-reported 80-week Phase 3 TRANSCEND-T2D-2 results comparing retatrutide with semaglutide 2 mg in adults with type 2 diabetes.
Novo Nordisk just launched a very interesting new obesity trial: OASIS 5.
The study is looking at whether lower maintenance doses of oral Wegovy (semaglutide tablets) can still produce meaningful weight loss.
This is important because the currently approved oral maintenance dose is 25 mg daily, but in real-world obesity care, not every patient necessarily needs the maximum dose to have a strong response.
OASIS 5 will enroll about 450 adults with overweight or obesity without diabetes and follow them for roughly 60 weeks. Participants will receive one of two lower oral semaglutide doses or placebo.
Importantly, Novo has not yet publicly disclosed the exact lower doses being studied.
Why does this matter? In clinical practice, we regularly see patients who:
- Have excellent appetite control and weight loss at lower doses
- Reach their treatment goals before reaching the maximum dose
- Experience fewer GI side effects at lower doses
- Would benefit from a more individualized maintenance strategy
We already know from OASIS 4 that oral semaglutide 25 mg produced approximately 16.6% mean weight loss at 64 weeks.
Now the question becomes: How much of that benefit can be maintained at lower doses?
If lower-dose oral Wegovy provides substantial weight loss with better tolerability and potentially lower cost, this could give clinicians much more flexibility in how we individualize obesity treatment.
I’ll be very interested to see the dose-response data when these results become available.